EMA validates Eisai & Nuvation Bio’s MAA for taletrectinib for the treatment of advanced ROS1-positive NSCLC: Tokyo Monday, March 30, 2026, 11:00 Hrs [IST] Eisai Co., Ltd., a hu ...
Every month, we share opportunities for artists and designers, including open calls, grants, fellowships, and residencies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results